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Introduction
During tumorigenesis, neoplastic cells must endure DNA dam-
age from environmental, metabolic, and other intrinsic sources 
(Bartkova et al., 2006; Halazonetis et al., 2008). Oncogene- 
induced DNA replication stress can be a major cause of intrinsic 
DNA damage and represents a potential source of genome in-
stability in cancer cells. Many oncogenes, including v-RAS, cy-
clin E, and others, induce DNA replication defects that trigger 
DNA damage signaling (including ATM–CHK2, ATR–CHK1, 
and p53) and lead to irreversible cell cycle exit often termed 
oncogene-induced senescence (OIS; Bartkova et al., 2006; 
Di Micco et al., 2006).
The precise mechanisms by which oncogenes induce 
DNA damage are incompletely understood. Oncogene-induced 
DNA damage has been attributed to induction of genotoxic re-
active oxygen species (ROS; DeNicola et al., 2011), depletion 
of nucleotide pools (Bester et al., 2011), collisions between the 
DNA replication and transcriptional machinery (Jones et al., 
2013), or aberrant reinitiation of DNA synthesis multiple times 
each per cell cycle—a process usually termed “rereplication” 
or “hyperreplication” (Di Micco et al., 2006). Rereplication 
likely generates “onion skin” DNA structures in which head-to-
tail collisions between replication forks produce double-strand 
breaks (DSBs; Davidson et al., 2006). It is unknown whether 
oncogene-induced rereplication is caused by inappropriate 
activation of DNA replication licensing factors, initiation fac-
tors, or deregulation of both licensing and initiation phases of 
DNA synthesis. It is also unclear whether common mechanisms 
mediate rereplication and DNA damage in response to all on-
cogenes. It is possible that the constitutive mitogenic signals 
induced by oncogenes culminate in aberrant cyclin-dependent 
kinase 2 (CDK2) activation, in turn leading to DNA rereplica-
tion and other replication defects. Indeed, oncogene-induced 
DNA replication stress is often modeled experimentally by 
overexpression of CDK2 activators (Cyclin E and CDC25A) or 
inhibition of the WEE1 kinase to remove negative constraints 
over CDK2 (Sogo et al., 2002; Bartkova et al., 2006; Beck et 
al., 2010, 2012; Jones et al., 2013).
Despite our limited mechanistic understanding of how 
oncogenes dysregulate DNA synthesis and cause DNA dam-
age, there is general consensus that OIS poses a barrier to 
tumorigenesis. Clearly, however, the OIS barrier is imperfect 
and can be breached. The precise mechanisms by which on-
cogene-expressing cells withstand replication stress and DNA 
damage are poorly understood. DNA repair and/or DNA dam-
The mechanisms by which neoplastic cells tolerate oncogene-induced DNA replication stress are poorly understood. 
Cyclin-dependent kinase 2 (CDK2) is a major mediator of oncogenic DNA replication stress. In this study, we show that 
CDK2-inducing stimuli (including Cyclin E overexpression, oncogenic RAS, and WEE1 inhibition) activate the DNA re-
pair protein RAD18. CDK2-induced RAD18 activation required initiation of DNA synthesis and was repressed by p53. 
RAD18 and its effector, DNA polymerase κ (Polκ), sustained ongoing DNA synthesis in cells harboring elevated CDK2 
activity. RAD18-deficient cells aberrantly accumulated single-stranded DNA (ssDNA) after CDK2 activation. In 
RAD18-depleted cells, the G2/M checkpoint was necessary to prevent mitotic entry with persistent ssDNA. Rad18−/− 
and Polκ−/− cells were highly sensitive to the WEE1 inhibitor MK-1775 (which simultaneously activates CDK2 and abro-
gates the G2/M checkpoint). Collectively, our results show that the RAD18–Polκ signaling axis allows tolerance of 
CDK2-mediated oncogenic stress and may allow neoplastic cells to breach tumorigenic barriers.
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age tolerance capacity could potentially impact whether DNA 
synthesis and viability are sustained when cells experience on-
cogenic stress. Interestingly, the DNA polymerase δ subunits 
POLD3 and POLD4 can facilitate DNA replication in cyclin 
E–overexpressing cells (Costantino et al., 2014). Moreover, 
the ATR–CHK1 pathway can promote oncogene-induced car-
cinogenesis (Schoppy et al., 2012). Therefore, DNA damage 
signaling and genome maintenance might critically influence 
whether oncogene-expressing cells breach the OIS barrier. 
However, there has been no systematic analysis of how DNA 
damage signaling and repair mechanisms impact DNA replica-
tion and cell cycle progression of oncogene-expressing cells. 
It remains to be investigated whether all genome maintenance 
mechanisms or only specific subpathways of the DNA damage 
response confer oncogenic stress tolerance. Importantly, many 
cancer chemotherapeutic agents act by causing DNA repli-
cation stress and DNA damage. The selective pressures for 
preneoplastic cells to acquire DNA damage tolerance during 
tumorigenesis could also provide a mechanism for chemore-
sistance. Therefore, the mechanisms by which cancer cells tol-
erate oncogenic DNA replication stress represent therapeutic 
targets whose inhibition could sensitize tumors to intrinsic and 
therapy-induced DNA damage.
We recently found that many cancer cells co-opt an ab-
errantly expressed meiotic protein, the cancer/testes antigen 
MAGE-A4, to pathologically activate trans-lesion synthesis 
(TLS; Gao et al., 2016a). Cancer cell–specific RAD18 pathway 
activation by MAGE-A4 first suggested to us a possible role 
for TLS in the tolerance of replicative stresses that are unique 
to neoplastic cells. TLS is a specialized mode of DNA repli-
cation involving the DNA damage–tolerant and error-prone 
Y family DNA polymerases η (Polη), κ (Polκ), and ι (Polι) 
as well as REV1 (Prakash et al., 2005). Individual TLS poly-
merases perform replicative bypass of preferred cognate DNA 
lesions. Collectively, the TLS polymerases support DNA rep-
lication and viability in cells harboring damaged genomes. Y 
family polymerase-deficient cells are often sensitive to agents 
that cause replication fork–stalling and DNA replication stress, 
demonstrating a key role for the TLS pathway in DNA dam-
age tolerance. However, owing to the low fidelity of Y family 
polymerases, TLS can be mutagenic (Prakash et al., 2005). 
Thus, TLS must be regulated stringently and used sparingly to 
maintain genome stability.
The E3 ubiquitin ligase RAD18 is a proximal activa-
tor of all four Y family TLS DNA polymerases (Hedglin and 
Benkovic, 2015). In response to DNA replication fork stalling, 
RAD18 monoubiquitinates proliferating cell nuclear antigen 
(PCNA) at the conserved residue K164. Y family DNA poly-
merases possess ubiquitin-binding (ubiquitin-binding motif 
[UBM] and ubiquitin-binding zinc finger [UBZ]) domains and 
PCNA-interacting peptide boxes that facilitate their preferential 
association with PCNA in its monoubiquitinated form (Bienko 
et al., 2005). The DNA damage–inducible interaction between 
TLS polymerases and PCNA is the basis for the polymerase 
switch that replaces replicative DNA polymerases ε and δ with 
Y family polymerases at stalled DNA replication forks. Polη 
exists in complex with RAD18 and is probably the default Y 
family TLS polymerase recruited to stalled DNA replication 
forks (Watanabe et al., 2004; Day et al., 2010). Polη is versa-
tile and can perform replicative bypass of many bulky lesions, 
possibly explaining why this TLS polymerase is preferentially 
recruited to all stalled replication forks.
In addition to its central role in TLS, RAD18 contrib-
utes to activation of other genome maintenance pathways, 
including the Fanconi Anemia pathway (Palle and Vaziri, 
2011; Williams et al., 2011), interstrand cross-link repair 
(Räschle et al., 2015), and DSB repair (Huang et al., 2009). 
As the apical component of the TLS polymerase switch and 
other DNA repair pathways, RAD18 expression levels and 
activity critically impact DNA damage sensitivity. In neo-
plastic cells, pathological activation of RAD18 by its stabi-
lizing binding partner MAGE-A4 has the potential to confer 
both DNA damage tolerance and mutability, two important 
hallmarks and enabling characteristics of tumor cells. Be-
cause oncogenic stress is a major source of intrinsic DNA 
damage experienced by cancer cells, we hypothesized a role 
for the RAD18 pathway in the tolerance of oncogene-induced 
DNA damage. We show in this study that RAD18 is acti-
vated in response to oncogenic stimuli that induce aberrant 
CDK2 activity. Moreover, RAD18 and its effector Y family 
DNA polymerase Polκ (but surprisingly not the default TLS 
polymerase Polη) are necessary for S phase progression and 
viability in the face of excess CDK2 activity. Collectively, 
this work suggests that TLS may be an important driver of 
carcinogenesis that promotes both tolerance of oncogenic 
stress and mutagenesis.
Results
Acute oncogene expression promotes 
RAD18-mediated PCNA monoubiquitination 
in untransformed cells
We determined whether the TLS branch of the DNA damage re-
sponse is activated in response to acute oncogene expression in 
human cells. We selected representative stimuli that are known 
to induce DNA replication stress and OIS, including Ha-RASV12, 
Cyclin E, c-MYC, and CDT1 (Bartkova et al., 2006; Liontos et 
al., 2007; Srinivasan et al., 2013). Oncogenes were transiently 
expressed in untransformed normal human fibroblasts (NHFs) 
using adenovirus vectors. 48  h after infection, overexpressed 
Cyclin E, C-MYC, and CDT1 proteins were readily detectable 
by immunoblotting, and MAPK phosphorylation was used to 
validate RAS pathway activation (Fig. 1 A).
As expected from previous work, DNA damage markers 
including CHK1 pS317 and γH2AX were induced by ectopi-
cally expressed Cyclin E and RAS (Fig. 1 A; Bartkova et al., 
2006; Di Micco et al., 2006; Neelsen et al., 2013a). PCNA 
monoubiquitination was not significantly affected by MYC 
or CDT1. However, levels of monoubiquitinated PCNA were 
increased 25-fold in response to overexpressed Ha-RAS and 
46-fold after Cyclin E expression. The fold changes in PCNA 
monoubiquitination after Ha-RAS and Cyclin E expression 
substantially exceeded the threefold increase in PCNA modi-
fication induced by UV irradiation in NHFs (Fig. 1 A, second 
lane from left). The levels of ectopically expressed cyclin E 
that induced PCNA monoubiquitination in untransformed NHF 
cells were similar to steady-state Cyclin E levels in various 
cancer cell lines including HCT116 colon cancer cells, A549 
and H1299 lung carcinoma cells, and HeLa cervical cancer 
cells (Fig. 1 B). In immunoprecipitation (IP) kinase assays, the 
CDK2 activity of Cyclin E–overexpressing cells was compa-
rable to CDK2 activity in the representative lung cancer cell 
line H1299 (Fig. 1 C). Therefore, our standard Cyclin E over-
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Figure 1. Oncogenic stimuli promote RAD18-mediated PCNA monoubiquitination. (A) Adenoviral vectors were used to express c-MYC, Ha-RASV12, CDT1, 
and Cyclin E in cultured NHF. After 48 h, cell lysates were analyzed by SDS-PAGE and immunoblotted with the indicated antibodies. (B) Immunoblot show-
ing relative Cyclin E protein levels in AdCyclin E–infected NHFs and various cancer cell lines. Soluble extracts from the indicated cells were normalized 
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expression conditions are appropriate for modeling the aberrant 
Cyclin E–CDK2 signaling of cancer cells.
In RAS-transformed BJ human fibroblasts (Hahn et al., 
1999), CDK2 activity was approximately fourfold higher than 
in isogenic parental BJ fibroblasts (Fig. 1 C) and was compa-
rable to CDK2 activity of AdCyclin E–transduced fibroblasts 
and H1299 lung cancer cells (Fig. 1 C). PCNA was constitu-
tively monoubiquitinated in BJ-RAS cells when compared 
with parental BJ fibroblasts (Fig. 1 D). Moreover, acute treat-
ment with the CDK2 inhibitor roscovitine attenuated PCNA 
monoubiquitination in BJ-RAS cells (Fig. 1 D). We conclude 
that Cyclin E– or RAS-induced CDK2 activity stimulates 
PCNA monoubiquitination.
As an additional approach to test the effect of CDK2 acti-
vation on PCNA monoubiquitination, we used a pharmacolog-
ical inhibitor of WEE1 kinase (MK-1775) to de-repress CDK2. 
Using IP–kinase assays, we confirmed that CDK2 was activated 
in MK-1775–treated cells (Fig. 1 C) as expected from previous 
work (Beck et al., 2012; Sørensen and Syljuåsen, 2012; Sakuri-
kar et al., 2016). Similar to ectopic Cyclin E or RAS expres-
sion, MK-1775 treatment induced PCNA monoubiquitination 
in NHFs (Fig. 1 E). The MK-1775–induced increases in CDK2 
activity and PCNA monoubiquitination (sixfold and 4.3-fold 
increases, respectively) were modest compared with AdCy-
clin E–induced CDK activity and PCNA monoubiquitination, 
indicating that MK-1775–induced CDK2 activity is limited by 
endogenous Cyclin E levels.
Because MK-1775 de-represses both CDK1 and CDK2, 
we sought to determine which CDK contributes to PCNA 
monoubiquitination when WEE1 is inhibited. In CDK1- 
depleted cells, MK-1775–induced PCNA monoubiquitina-
tion was attenuated when compared with CDK1-replete cells 
(Fig. S1 A), possibly suggesting that CDK1 contributes to 
PCNA monoubiquitination. However, CDK1-depleted cells 
were arrested in G2/M (Fig. S1 B), potentially causing at-
tenuation of PCNA monoubiquitination indirectly after cell 
cycle arrest. Therefore, as an alternative approach to de-
termining the potential roles of CDK2 and CDK1 in stim-
ulating PCNA monoubiquitination, we tested the effects of 
specific CDK2 activators (Cyclins E and A) or CDK1 acti-
vators (Cyclin B and CDC25C) on PCNA. As shown in Fig. 
S1 (C and D), PCNA monoubiquitination was induced by 
Cyclin E and more modestly by Cyclin A, but not by Cy-
clin B or CDC25C. We infer that MK-1775–induced PCNA 
monoubiquitination is primarily caused by de-repression of 
CDK2 and is not CDK1 mediated. Collectively, Fig. 1 (A–E) 
and Fig. S1 show that deregulated CDK2 signaling triggers 
PCNA monoubiquitination in untransformed human cells. 
PCNA was also monoubiquitinated in response to aberrant 
CDK2 activity in other cell types that have been used ex-
tensively to model cellular responses to oncogenic stress, 
including mouse embryonic fibroblasts (MEFs) and U2OS 
cells (as shown in Figs. 1 F and 4).
PCNA is a substrate for monoubiquitination by sev-
eral E3 ligases including RAD18 (Watanabe et al., 2004), 
CRL4Cdt2 (Terai et al., 2010), and HLTF (Lin et al., 2011). 
However, Cyclin E overexpression induced the formation of 
RAD18 nuclear foci (Fig. 1 G). Moreover, MK-1775–induced 
PCNA monoubiquitination was attenuated in RAD18-depleted 
NHFs and in Rad18−/− MEFs relative to isogenic RAD18- 
replete cells (Fig. 1, E and F). Ectopically expressed siRNA- 
resistant RAD18 fully rescued the PCNA monoubiquitination 
defect of RAD18-depleted cells (Fig. 1 H). Therefore, we con-
clude that PCNA monoubiquitination in response to elevated 
CDK2 is RAD18 mediated.
Cyclin E–CDK2–induced PCNA 
monoubiquitination requires replication 
licensing and origin firing
Cyclin E–CDK2 is active in both G1 and S phase, and 
RAD18-mediated PCNA monoubiquitination can occur 
throughout the cell cycle (Daigaku et al., 2010; Zlatanou et al., 
2011; Diamant et al., 2012; Yang et al., 2013). Therefore, we 
investigated the cell cycle stage specificity and proximal trigger 
of PCNA monoubiquitination in response to aberrant Cyclin E–
CDK2 activity. First, we asked whether PCNA monoubiquitina-
tion was associated with the imbalance of licensing or initiation 
phases of DNA replication. We ectopically overexpressed DNA 
replication licensing factors (CDT1 and CDC6) or Cyclin E to 
stimulate replication licensing or initiation of DNA synthesis, 
respectively. As expected, Cyclin E led to increased chromatin 
binding of CDC45 (a distal and rate-limiting step in the ini-
tiation of DNA synthesis) coincident with increased PCNA 
monoubiquitination (Fig. 2 A). Overexpressed licensing factors 
did not promote chromatin binding of CDC45 and induced neg-
ligible changes in PCNA monoubiquitination (Fig. 2 A). There-
fore, RAD18 activation is associated with aberrant initiation of 
DNA synthesis, not altered replication licensing.
In a complementary approach to test the relationship 
between PCNA monoubiquitination and initiation of DNA 
synthesis, we used p53-directed shRNA or expressed the high-
risk HPV-E6 oncoprotein to abrogate the G1 checkpoint and 
increase initiation of DNA synthesis. As expected, p53 deple-
tion promoted chromatin binding of CDC45 (Fig. 2 B) and S 
phase entry (Fig. 2 C) while also coincidently inducing PCNA 
monoubiquitination (Fig. 2 B). Similarly, acute Wee1 inhibition 
in asynchronous HPV-E6–expressing 3T3 cells led to a 4.7-fold 
increase in PCNA monoubiquitination when compared with 
p53-replete 3T3 cells (Fig. 2 D). The results of Fig. 2 (B–D) 
suggest that loss of the G1 checkpoint and the ensuing increases 
in S phase entry and origin firing lead to increased PCNA 
monoubiquitination. We considered the possibility that p53 loss 
for protein concentration and then analyzed by SDS-PAGE and immunoblotting using antibodies against Cyclin E and GAP DH (for loading controls). (C) 
IP–kinase assay showing relative CDK2 activities in RAS-transformed cells (BJ-RAS) and isogenic parental fibroblasts (BJ). Also shown are CDK2 activities 
in control, MK-1775–treated, and Cyclin E–overexpressing NHFs and in H1299 lung adenocarcinoma cells. (D) Immunoblot showing the effects of 24 h 
roscovitine treatment on PCNA monoubiquitination in BJ and BJ-RAS cells. (E) Control and RAD18-depleted NHF cells were treated for 0–7 h with MK-1775. 
At different times, cell lysates were analyzed for expression of the indicated DNA damage markers using SDS-PAGE and immunoblotting. (F) Rad18+/+ 
and Rad18−/− MEFs were treated with MK-1775 for 7 h. Lysates from the resulting cells were analyzed by SDS-PAGE and immunoblotted with indicated 
antibodies. (G) U2OS cells were coinfected with AdCFP-RAD18 and AdCyclin E (or with control adenovirus) for 24 h. Some cultures were UV irradiated 
(20 J/m2), and 2 h later, CFP-RAD18 subcellular distribution was analyzed by confocal microscopy. Bar, 10 µm. (H) NHFs were transfected with siRAD18 
or with nontargeting control siRNA. Transfected cells were infected with adenoviruses encoding siRNA-resistant RAD18, Cyclin E, or with an “empty” virus 
for control. Lysates from the resulting cells were analyzed by SDS-PAGE and immunoblotted with the indicated antibodies.
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Figure 2. Passage through the G1/S restriction point and initiation of DNA synthesis are necessary for CDK2-induced PCNA monoubiquitination. (A) NHFs 
were infected with the indicated adenoviral vectors for 24 h, and cell lysates were analyzed by SDS-PAGE and immunoblotted with the indicated antibod-
ies. (B) Replicate cultures of NHFs and shp53-NHF cells were transfected with siRAD18 or control nontargeting RNA. The resulting cultures were infected 
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might directly promote PCNA monoubiquitination. However, 
when we inhibited Wee1 in S phase–synchronized cultures, 
HPV E6 expression did not affect PCNA monoubiquitination 
(Fig. 2 E). Moreover, Wee1 inhibition before S phase did not 
induce PCNA monoubiquitination (Fig.  2  E). Therefore, p53 
limits CDK2-induced PCNA monoubiquitination by enforcing 
a G1/S checkpoint and preventing S phase entry.
To test whether Cyclin E–induced PCNA monoubiquiti-
nation was dependent on initiation of DNA replication, we 
used pharmacological inhibition of CDK2 and gene silencing 
of CDC7 to inhibit protein kinase activities that are essential 
for origin firing. Fig. 2 (F and G) show that CDK2 and CDC7 
are necessary for Cyclin E–induced PCNA monoubiquitina-
tion. As expected, silencing of CDC6, which limits the number 
of licensed origins available for initiation of DNA synthesis, 
also abrogated Cyclin E–induced PCNA monoubiquitination 
(Fig. 2 G). We conclude that CDK2-induced PCNA monoubiq-
uitination requires passage through the G1/S restriction point 
and initiation of DNA synthesis.
MUS81 and replication protein A (RPA) 
contribute to RAD18 pathway activation
The mechanism of RAD18 activation during S phase has been 
attributed to its direct association with p95/NBS1 (Yanagihara 
et al., 2011), with RPA-coated single-stranded DNA (ssDNA; 
Davies et al., 2008; Tsuji et al., 2008), or with ubiquitinated 
chromatin generated by the E3 ligase RNF8 (Huang et al., 
2009) at damaged replication forks.
Levels of chromatin-bound p95/NBS1 and RNF8 were 
not increased upon Cyclin E overexpression (Fig. 3 A). More-
over, depletion of p95/NBS1 or RNF8 did not affect Cyclin E–
induced PCNA monoubiquitination (Fig. 3 A), suggesting that 
p95/NBS1 and RNF8 do not mediate RAD18 pathway activa-
tion in response to excess CDK2. However, Cyclin E overex-
pression and MK-1775 treatment both led to increased numbers 
of nuclear RPA foci (Fig. 3 B) and increases in chromatin-bound 
RPA (Fig. 3, A and C), coincident with PCNA monoubiquitina-
tion. Moreover, Cyclin E–induced PCNA monoubiquitination 
was attenuated in RPA-depleted cells (Fig. 3 A). WEE1 inhi-
bition was previously shown to cause an increase in levels of 
ssDNA (Beck et al., 2010) and in alkaline COM ET assays, Cy-
clin E overexpression led to a 27-fold increase in ssDNA levels 
relative to control cultures (Fig. 3 D). Collectively, our results 
are most consistent with an RPA-ssDNA–mediated RAD18 ac-
tivation mechanism in response to excess CDK2 activity.
Nucleoside depletion has been postulated as a mechanism 
for replication defects in response to certain oncogenic stimuli 
(Bester et al., 2011). However, exogenously added nucleosides 
did not suppress the Cyclin E–induced PCNA monoubiquiti-
nation (Fig. 3 E). Therefore, we consider it most likely that the 
PCNA monoubiquitination induced by elevated CDK2 activity 
does not result from limited availability of nucleotide pools.
CDK2-induced aberrant DNA replication structures are 
substrates for nucleolytic cleavage by MUS81 (Neelsen et al., 
2013a). Beck et al. (2012) showed that MUS81 is recruited to 
stalled forks when WEE1 kinase is inhibited. Moreover, MUS81 
is known to process stalled replication forks to generate the 
RPA-ssDNA that triggers CHK1 pathway activation (Regairaz 
et al., 2011). Therefore, we used gene silencing to test a possi-
ble role for MUS81 in RAD18 pathway activation. As expected 
from a previous study (Regairaz et al., 2011), levels of chroma-
tin-bound pRPA (pS4/8) and pChk1 (S317) were reduced after 
MUS81 depletion (Fig. 3 F). Interestingly, MK-1775–induced 
PCNA monoubiquitination was attenuated in MUS81-depleted 
cells (Fig. 3 F). BrdU labeling rates and cell cycle profiles were 
unaffected by MUS81 depletion (Fig. 3 F). Therefore, the re-
duced PCNA monoubiquitination of MUS81-depleted cells was 
not secondary to an altered S phase.
We used a flow cytometry–based assay to determine 
relative levels of MK-1775–induced ssDNA in control and 
MUS81-depleted cells. The flow-based ssDNA assay is a 
modified version of a previously published protocol for visu-
alizing ssDNA regions (Raderschall et al., 1999) and was vali-
dated as described in Fig. S2. As shown in Fig. 3 G, MK-1775 
led to an approximately twofold increase in ssDNA levels in 
MUS81-replete cells. However, WEE1 inhibition did not in-
duce ssDNA in MUS81-depleted cultures (Fig. 3 G). We con-
clude that certain CDK2-induced aberrant DNA replication 
intermediates can be processed by MUS81 to generate RPA-
ssDNA, which in turn serves as a common trigger for both 
RAD18 and CHK1 pathways. 
In Cyclin E–expressing cells (in which CDK2 activity was 
∼2.6-fold higher than in MK-1775–treated cells under our stan-
dard experimental conditions; see Fig. 1 C), PCNA monoubiq-
uitination was very modestly reduced after MUS81 depletion 
(Fig. 3 H). As noted previously (Neelsen et al., 2013a), the stan-
dard conditions used to express Cyclin E generate severe DNA 
replication defects, irreversible cell cycle arrest, and massive 
amounts of ssDNA in all cells. Therefore, MUS81-independent 
processing of DNA replication intermediates also contributes 
to PCNA monoubiquitination after the severe replication stress 
from overexpressed Cyclin E.
Cyclin E–induced PCNA monoubiquitination 
specifically regulates Polκ
To identify relevant effectors of genome maintenance in re-
sponse to excess CDK2 signaling, we investigated the regu-
lation of Y family DNA polymerases. Of the Y family DNA 
polymerases examined (Polη, Polκ, and Polι), only Polκ was 
redistributed to chromatin in response to overexpressed Cyclin 
with the indicated viruses. One plate of each replicate culture was analyzed by SDS-PAGE and immunoblotted with the indicated antibodies. The other 
plate of each replicate pair was pulse labeled with BrdU for 1 h. The resulting cultures were costained with propidium iodide and BrdU and then analyzed 
for cell cycle distribution as shown in C. The white dotted line serves to separate the NHF and shp53-NHF data for easier comparison of protein levels 
between the two cell lines. (C) Graphs summarizing the distribution of cells between different cell cycle phases for each experimental condition. (D) Swiss 
3T3-XSN and 3T3-E6 cells were transfected with siRAD18 or with nontargeting siRNA and then treated with the indicated concentrations of MK-1775 for 
5 h. Cell lysates were analyzed by SDS-PAGE and immunoblotting with the indicated antibodies. (E) Quiescent (G0) cultures of Swiss 3T3-XSN and 3T3-E6 
cells were stimulated with 10% serum. At 8 and 16 h after serum stimulation (time points corresponding to mid-G1 and S phase, respectively), cells were 
treated with MK-1775 for 5 h before harvest, SDS-PAGE, and immunoblot analysis of the indicated proteins. (F) NHFs were infected with AdCyclin E (or 
empty vector for control) for 24 h. The resulting cultures were treated with roscovitine for 2 h before harvest for SDS-PAGE and immunoblot analysis. (G) 
NHFs were transfected with siCDC6, siCDC7, or nontargeting RNA duplexes. The resulting cultures were infected with AdCyclin E (or empty adenoviral 
vector). 48 h later, cells were harvested for SDS-PAGE and immunoblotting with the indicated antibodies.
rAD18 confers oncogenic stress tolerance • Yang et al. 3103
Figure 3. CDK2-induced PCNA monoubiquitination is p95/NBS1-independent but requires MUS81. (A) NHFs were transfected with siNBS1, siRPA32, 
siRNF8, siCHK1, or control nontargeting siRNA. The resulting cultures were infected with AdCyclin E or control adenovirus, and 48 h later, cells were har-
vested for SDS-PAGE and immunoblot analysis. (B) Replicate cultures of NHFs were infected with AdCyclin E for 24 h, treated with MK-1775 for 5 h, or left 
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E (Fig. 4 A). Cyclin E overexpression also induced association 
of Polκ with PCNA as determined by coimmunoprecipitation 
experiments (Fig.  4  B). In immunofluorescence microscopy 
studies, Cyclin E overexpression and WEE1 inhibition both 
led to an increase in GFP-Polκ foci (Fig.  4  C). As expected 
from previous work, YFP-Polη formed constitutive nuclear 
foci in replicating cells, but numbers of YFP-Polη nuclear foci 
were unaffected by Cyclin E expression or WEE1 inhibition 
(Fig.  4  D; Durando et al., 2013). Collectively, the results of 
Fig. 4 suggest that Polκ is recruited to CDK2-induced aberrant 
DNA replication intermediates.
Rad18 and Polκ sustain ongoing DNA 
replication and cell viability after Wee1 
inhibition
The results of Figs. 1, 2, 3, and 4 suggested a possible role for 
TLS in tolerating the aberrant S phase induced by excessive 
CDK2 activity. To elucidate the contribution of TLS to ongoing 
DNA synthesis in cells harboring excess CDK2, we compared 
DNA replication dynamics of MK-1775–treated Polk−/− MEFs 
with isogenic (Polk+/+) control cells.
As shown by the DNA fiber analyses in Fig. 5 (A and B), 
DNA replication fork velocities were reduced by 15% after 5 h 
of Wee1 inhibition in the Polk+/+ MEFs. However, in Polk−/− 
cells, Wee1 inhibition led to a 44% reduction of fork velocity. 
New origin firing was increased approximately twofold after 
WEE1 inhibition in both Polk+/+ and Polk−/− MEFs. In NHFs, 
increased Cyclin E expression (driven by a stably integrated 
doxycycline-inducible expression vector) led to a 23% decrease 
in replication fork velocities (Fig.  5  C). However, in Polκ- 
depleted fibroblasts, replication fork velocities were reduced 
by 63% after Cyclin E induction (Fig. 5 C). Replication fork 
velocities were unaffected by Polη depletion (Fig. 5 C). We con-
clude that Polκ-dependent TLS sustains DNA replication fork 
progression in cells harboring elevated CDK activity.
In genotoxin-treated cells, TLS prevents DNA replica-
tion fork collapse and DNA DSB accumulation (Bi et al., 2005, 
2006). To determine whether TLS also protects against DSB 
formation caused by excessive CDK2, we enumerated 53BP1 
nuclear foci (as a surrogate for unrepaired DSBs) in Cyclin 
E–overexpressing cells that were depleted of RAD18, Polκ, or 
Polη. As shown in Fig. 5 D, silencing of RAD18 or Polκ (but 
not Polη) led to an approximately twofold increase in the num-
ber of 53BP1 foci in Cyclin E–overexpressing cells. The results 
of Fig. 5 (A–D) suggest that RAD18 and Polκ (but not Polη) 
sustain DNA replication and prevent DSB accumulation in Cy-
clin E–overexpressing cells.
TLS operates postreplicatively and patches 5′ ssDNA 
gaps generated behind nascent leading strands (Lopes et al., 
2006; Daigaku et al., 2010). We predicted therefore that TLS 
deficiency would lead to persistent ssDNA when there is ex-
cess CDK2. To test this prediction, we used flow cytometry to 
compare ssDNA levels in Polk+/+ and Polk−/− cells basally and 
after Wee1 inhibition. As shown in Fig. 5 E, basal ssDNA levels 
were indistinguishable between exponentially growing Polk+/+ 
and Polk−/− cells. However, after Wee1 inhibition, Polk−/− MEFs 
accumulated up to 10-fold higher levels of ssDNA than isogenic 
Polk+/+ cells (Fig. 5 E). The ssDNA induced by Wee1 inhibition 
in Polk−/− cells coincided with 4N (G2 + M) populations iden-
tified by propidium iodide staining (Fig. 5 E). Using anti–phos-
pho–histone H3 (to more precisely define mitotic populations), 
we demonstrated that mitotic Polk-deficient MEFs accumulated 
approximately fivefold higher levels of ssDNA after Wee1 inhi-
bition when compared with Polk+/+ cells (Fig. 5 F). We conclude 
that Polκ is important to prevent mitotic ssDNA accumulation 
in response to Wee1 inhibition.
Persistent ssDNA triggers the “replication checkpoint,” a 
CHK1-mediated mechanism that inhibits CDC2/CDK1 via Y15 
phosphorylation and prevents mitosis when the genome is in-
completely replicated (Canman, 2001). In NHFs, RAD18 deple-
tion led to an increase in Y15-phosphorylated CDC2 (Fig. 6 A), 
indicating that the replication checkpoint is activated when TLS 
is compromised. As expected, WEE1 inhibition eliminated the 
Y15 phosphorylation in RAD18-depleted cells (Fig. 6 A).
We hypothesized that the persistent ssDNA induced by 
MK-1775 in TLS-deficient cells resulted from aberrant activa-
tion of CDK2 (which deregulates DNA synthesis) and CDK1 
(which abrogates the G2/M checkpoint). To test whether the 
G2/M checkpoint is a failsafe when TLS is compromised, 
we used ectopically overexpressed CDC25C (a Y15-directed 
CDK1 phosphatase) as an MK-1775–independent strategy 
to bypass the G2/M checkpoint. As expected, overexpressed 
CDC25C caused a reduction in levels of Y15-phosphorylated 
CDK1 (Fig. S3 A). We determined the effects of CDC25C on 
mitotic ssDNA in RAS-transformed BJ cells (which have high 
CDK2 activity as shown in Fig. 1 C) and parental BJ fibroblasts. 
As shown in Fig. S3 C, CDC25C overexpression led to an ∼20-
fold increase in mitotic ssDNA levels in RAS-transformed cells 
but not in parental BJ fibroblasts. Interestingly, in RAD18- 
depleted BJ-RAS cells, levels of mitotic ssDNA were further in-
creased to ∼29-fold above control (Fig. S3 C). In three separate 
untreated for controls. The resulting cells were fixed, stained with anti-RPA 32 and DAPI, and analyzed by confocal microscopy. The images represent rep-
resentative fields of RPA- and DAPI-stained nuclei. At least 100 cells were scored for each experimental condition. Bar, 10 µm. (C) NHFs were transfected 
with siRAD18 or nontargeting siRNA and then treated with MK-1775 for 5 h. Cells were harvested and analyzed by SDS-PAGE and immunoblotting with 
the indicated antibodies. (D) NHFs were infected with the indicated adenoviruses for 48 h. Nuclei from the resulting cultures were analyzed using alkaline 
and neutral comet assays. 50 tail moments were measured for each experimental condition. To determine the statistical significance of the differences in 
single-strand break (SSB) and DSB levels, we performed ANO VA between groups followed by Tukey’s multiple comparison of means test. Results of the 
Tukey test indicated significant differences between AdCon and AdCyclin E–overexpressing cells (P < 0.001), indicating that Cyclin E expression induces 
single-strand breaks and DSBs. The result shown is representative of two independent experiments that yielded qualitatively similar results. ***, P < 0.001. 
(E) NHFs were grown for 48 h in complete medium or medium supplemented with 50 µM of all four nucleosides (A, U, C, and G) and increasing doses 
of AdCyclin E (ranging from 0.05−1.0 × 1010 pfu/ml). Chromatin fractions from the resulting cells were analyzed by immunoblotting with the indicated 
antibodies. (F) NHFs were transfected with siMUS81 and nontargeting control siRNAs for 48 h. The resulting cultures were treated with the indicated doses 
of MK-1775 for 5 h before harvest for SDS-PAGE and immunoblot analysis with the indicated antibodies. For siMUS81 and siCon-transfected cultures, one 
replicate plate was pulse labeled with 10 µM BrdU and analyzed by flow cytometry to quantify S phase–positive populations. (G) Replicate plates of NHFs 
were transfected with the indicated siRNAs for 48 h. One plate of each replicate pair was treated with MK-1775 for 5 h before flow cytometry analysis of 
ssDNA. (H) U2OS cells were transfected with siMUS81 or nontargeting control (siCon) RNAs. 24 h after transfection, cultures were infected with AdCyclin 
E or AdCon. After 24 h, cells were collected and analyzed by SDS-PAGE and immunoblotting with the indicated antibodies.
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experiments, RAD18 depletion increased the levels of RAS- 
induced ssDNA by 1.4-fold ± 0.16 (P = 0.028). Collectively, the 
results of Fig. S3 indicate that in the absence of TLS, CDK2- 
induced ssDNA persists into mitosis when the replication 
checkpoint is bypassed by CDK1.
Forced bypass of the replication checkpoint can elicit 
premature chromatin condensation (PCC), abortive mitoses 
(termed “mitotic catastrophe”), and cell death (Nghiem et al., 
2001). To determine whether TLS averts mitotic catastrophe, 
we analyzed metaphase spreads from Rad18−/− and Polk−/− 
MEFs and isogenic WT cells after MK-1775 treatment and 
scored metaphase chromosomes for PCC.
Images of representative metaphase spreads illustrating 
normal mitotic chromosomes and pulverized chromosomes 
caused by PCC are shown in Fig.  6 B.  In control (MK-1775 
untreated) MEFs, the incidence of spontaneous PCC was neg-
ligible (<1%) in WT, Rad18−/−, and Polk−/− cultures, indicating 
minimal mitotic defects when TLS alone is compromised. After 
MK-1775 treatment, the incidence of PCC increased to 14% 
and 8% in Rad18+/+ and Polk+/+ MEFs, respectively (Fig. 6 C). 
Remarkably, the numbers of nuclei undergoing PCC were 3.1- 
and 4.4-fold higher in Rad18−/− and Polk−/− MEFs, respectively, 
when compared with isogenic WT control cells (Fig. 6 C). In 
clonogenic survival assays, both Rad18−/− and Polk−/− MEFs 
were sensitive to Wee1 inhibition when compared with WT 
cell lines (Fig. 6, D and E). We conclude that Rad18 and Polκ 
are important for preventing PCC and maintaining viability 
when Wee1 is inhibited.
To test whether Polκ is specifically required to tolerate 
aberrant CDK activity, we also determined the MK-1775 sen-
sitivity of an XP-variant (XPV) cell line (XP30RO), which 
harbors an inactivating mutation in Polη (Volpe and Cleaver, 
1995). In contrast with Polk-null MEFs, Polη-deficient XPV 
fibroblasts were not MK-1775 sensitive when compared with 
isogenic Polη-complemented (XP30RO + Polη) cells. Surpris-
ingly, Polη-deficient XP30RO cells were significantly more tol-
erant of WEE1 inhibition when compared with the corrected 
XP30RO + Polη line (Fig. 6 E). To further test the role of Polη 
on MK-1775 tolerance, we compared the MK-1775 sensitiv-
ity of MEFs derived from transgenic knock-in mice express-
ing WT RAD18 or a Polη interaction-deficient RAD18 DC2 
mutant (Yang et al., 2016). Cells expressing RAD18 DC2 are 
compromised for Polη activation and have modest UV sensi-
tivity (Watanabe et al., 2004; Day et al., 2010). Interestingly, 
Figure 4. Cyclin E overexpression and WEE1 in-
hibition promote nuclear redistribution and PCNA 
binding of Polκ. (A) U2OS cells were infected 
with 0, 108, and 1010 pfu/ml of AdCyclin E. 48 h 
later, chromatin extracts from the resulting cells 
were analyzed by SDS-PAGE and immunoblot-
ting with the indicated antibodies. (B) U2OS cells 
were infected with AdCyclin E, AdHA-PCNA, and 
AdGFP-Polκ as indicated. 24 h later, solubilized 
chromatin fractions were prepared and analyzed 
directly by SDS-PAGE (“input”) or were first immu-
noprecipitated with anti-HA (IP) to recover PCNA 
complexes, which were analyzed for the presence 
of associate GFP-Polκ. (C and D) Replicate cultures 
of U2OS cells were infected with GFP-Polκ (C) or 
YFP-Polη (D) adenovirus for 24  h.  The resulting 
cultures were infected with AdCyclin E for 24 h, 
were treated with MK-1775 for 5 h, or were left 
untreated for controls. The subcellular distributions 
of GFP-Polκ and YFP-Polη were analyzed by fluor-
escence microscopy, and representative images 
of TLS polymerase–expressing nuclei are shown. 
Bars, 10 µm. For quantitative analysis of DNA 
polymerase foci, at least 100 nuclei were scored 
for each experimental condition. The results are 
compiled from three independent experiments. 
Error bars represent SEM. Statistical analyses 
were performed using Student’s t test. The differ-
ences in numbers of foci between experimental 
conditions were significant for GFP-Polκ (**, P < 
0.01) but not significant for YFP-Polη (P > 0.05).
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Figure 5. Polκ facilitates DNA replication and prevents ssDNA accumulation in cells with elevated CDK2 activity. (A and B) DNA fiber analyses showing 
effects of MK-1775 treatment on DNA replication dynamics in cultures of isogenic WT and Polk−/− MEFs. Panel A shows results of a representative experi-
ment in which fork velocities were determined for 50 individual replication tracts under each experimental condition. Based on the results of ANO VA and 
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similar to Polη-deficient XPV cells, RAD18 DC2 MEFs were 
MK-1775 resistant when compared with WT RAD18-express-
ing MEFs (Fig. 6 G). Therefore, Polκ is specifically required to 
tolerate excessive CDK activity, and Polη inhibits tolerance of 
CDK2-induced replication stress.
To extend our analysis of Rad18 functions in tolerance 
of excess CDK2 activity, we also determined the role of Rad18 
in cellular response to oncogenic RAS. Rad18+/+ and Rad18−/− 
MEFs were transduced with retroviruses encoding oncogenic 
RAS or with an empty vector. As shown in Fig. 6 H, growth 
curves of empty vector–transduced Rad18+/+ and Rad18−/− cells 
were identical. However, RAS expression stimulated prolifera-
tion of Rad18+/+ MEFs but was inhibitory for Rad18−/− cells. 
These results further demonstrate that Rad18 facilitates toler-
ance of oncogenic stress.
Rad18 deficiency sensitizes cancer cells 
and Brca1-deficient cells to Wee1 inhibition
Because MK-1775 is being considered as a therapeutic agent, 
we determined the extent to which RAD18 signaling allows 
cancer cell lines to tolerate WEE1 inhibition. As shown in 
Fig. 7 (A–C), three representative and commonly studied can-
cer cell lines, H1299, A549, and U2OS, were MK-1775 sensi-
tive after RAD18 depletion.
Sensitivity to replicative stress is likely determined by 
the repertoire of available DNA damage tolerance pathways. 
Therefore, we sought to identify the DNA repair mechanisms 
that cooperate with RAD18 to confer tolerance of MK-1775–
induced stress. TLS deficiency predisposes to DSB forma-
tion (Fig. 5 D). Therefore, we determined the contributions 
of the two major S phase–coupled DSB repair processes (ho-
mologous recombination [HR] and θ-mediated end joining 
[TMEJ]) to MK-1775 tolerance in Polk-deficient cells. We 
used lentivirally expressed single guide RNAs (sgRNAs) to 
functionally inactivate Brca1 or Polq genes (encoding essen-
tial mediators of HR and TMEJ, respectively) in Polk+/+ or 
Polk−/− MEFs. As shown in Fig.  7  D, disruption of Brca1 
led to increased MK-1775 sensitivity of both Polk+/+ and 
Polk−/− MEFs, indicating that the HR and TLS jointly (and 
independently) facilitate tolerance MK-1775–induced DNA 
damage. As shown in Fig. S4, Polq-deficient MEFs were 
MK-1775 sensitive, also indicating a role for TMEJ in toler-
ance of CDK2-induced DSBs. However, inactivating the Polq 
gene did not increase the MK-1775 sensitivity of Rad18−/− or 
Polk−/− MEFs (Fig. S4). Collectively, these results indicate 
that there is partial redundancy between TLS and HR (but 
not between TLS and TMEJ) for MK-1775 tolerance. These 
findings validate RAD18-Polκ as a therapeutic target path-
way for augmenting MK-1775–induced lethality in cancer 
cells, particularly those with HR defects.
Discussion
It is widely accepted that diverse oncogenes induce DNA 
replicative stresses that in turn activate canonical DNA dam-
age signaling and repair pathways (Halazonetis et al., 2008). 
Many bona fide oncogenes including RAS induce CDK2 ac-
tivity (Fikaris et al., 2006). The high-level CDK2 activity of 
oncogene-expressing cells is a likely source of DNA replication 
stress. We show in this study that three independent CDK2-acti-
vating stimuli (oncogenic RAS, Cyclin E, and WEE1 inhibition) 
induce a DNA damage response that involves TLS pathway 
activation. Interestingly, Soria et al. (2006) previously showed 
that p21–CDK2 interactions suppress PCNA monoubiquitina-
tion and speculated that CDK activity may promote TLS—a 
prediction borne out by our results.
The precise nature of the aberrant DNA replication struc-
tures induced by oncogenic stimuli or excess CDK activity is 
not well understood. Rereplication resulting in initiation of 
DNA synthesis more than once per S phase may be a major 
mechanism of oncogene-induced DNA replication stress and 
DNA damage (Bartkova et al., 2006; Di Micco et al., 2006). 
Rereplication induces ssDNA gaps and replication fork reversal 
(Neelsen et al., 2013b) that eventually lead to DSB and check-
point activation (Vaziri et al., 2003). The ssDNA generated by 
rereplicating DNA provides a potential mechanism for acti-
vation of both CHK1 and RAD18 pathways. However, CDT1 
overexpression or geminin depletion—treatments that induce 
massive relicensing and rereplication (Vaziri et al., 2003)—
triggered modest PCNA ubiquitination when compared with 
Cyclin E overexpression or MK-1775 treatment. Therefore, 
rereplication intermediates may not be the sole mediators of 
CDK2-induced TLS pathway activation.
Tukey’s multiple comparison of means test, MK-1775 treatment led to statistically significant decreases in fork velocity in Polk−/− MEFs (P < 0.001) but not 
Polk+/+ cells (P > 0.05). To quantify new origin firing, 300 fibers were counted for each experimental condition. There were no significant differences in 
numbers of new origins when comparing between Polk−/− and Polk+/+ MEFs. In panel B, lengths of ongoing replication forks (containing both CldU and 
IdU) were measured to determine the distribution of replication fork speeds. 50 fibers were quantified for each experimental condition. The experiment 
described in A and B was repeated twice with similar results. (C) DNA fiber analyses showing effects of doxycycline (Dox)-inducible Cyclin E expression 
on DNA replication dynamics of Polκ- or Polη-depleted NHFs. DNA replication fork velocities were determined for 150 individual replication tracts from 
each experimental condition. Based on the results of ANO VA and Tukey’s multiple comparison of means test, doxycycline-inducible Cyclin E expression 
led to statistically significant reduction of fork velocity by in siPOLK-transfected NHFs (P < 0.001) but not siPOLH-transfected cells (P > 0.05). The data 
presented are representative of an experiment that was repeated twice with similar results. (D) Replicate cultures of U2OS cells were transfected with the 
indicated siRNAs. After 48 h, cells were treated with 2.5 µM MK-1775 (or vehicle for control) for 5 h. Cells were fixed, and 53BP distribution was analyzed 
by immunofluorescence confocal microscopy. Representative images of 53BP1-stained nuclei are shown. Bar, 10 µm. For quantitative analysis of DNA, 
at least 100 nuclei were scored for each experimental condition. The graph shows results of three independent experiments, and error bars represent 
SEM. Statistical analyses were performed using a Student’s t test. The resulting p-values indicate significant differences in numbers of 53BP1 foci between 
siCon and siPOLK (P < 0.05) and between siCon and siRAD18 (P < 0.01), but no significant differences between siCon and siPOLH-transfected cells. 
(E) Replicate cultures of isogenic Polk+/+ and Polk−/− MEFs were treated with 2.5 µM MK-1775 for the indicated times and then analyzed for ssDNA content 
using flow cytometry. For the 0- and 5-h time points, one plate of each replicate culture was collected for SDS-PAGE and immunoblotting with the indicated 
antibodies. PI, propidium iodide. (F) Polk+/+ and Polk−/− MEFs were prelabeled with BrdU for 24 h and then treated with 2.5 µM MK-1775 (or vehicle) for 
5 h. Cultures were analyzed by flow cytometry to identify phospho–histone H3– and ssDNA-positive populations. The histogram shows the results from 
three independent experiments in which the columns represent means and error bars represent the range. From the results of ANO VA and Tukey’s multiple 
comparison of means test, MK-1775 treatment induced statistically significant increases in ssDNA levels in Polk−/− MEFs (P < 0.001) but not in Polk+/+ cells 
(P = 0.8). *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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Figure 6. Polκ is specifically required to prevent PCC and confer viability after WEE1 inhibition. (A) U2OS cells were transfected with siRAD18, siWEE1, 
or nontargeting control RNA. 48 h later, cells were analyzed by SDS-PAGE and immunoblotting with the indicated antibodies. (B and C) Replicate cultures 
of isogenic Polk+/+ and Polk−/− MEFs were treated with 2.5 µM MK-1775 (or vehicle) for 7 h. Metaphase spreads from the resulting cells were analyzed by 
light microscopy and scored for aberrant nuclei undergoing mitotic catastrophe. Molecular masses are given in kilodaltons. Panel B shows representative 
examples of normal metaphase spreads and of pulverized nuclei displaying hallmarks of PCC. Bars, 10 µm. The histogram in C shows the effect of Polk 
and Rad18 on the relative incidence of PCC in control and MK-1775–treated cells. The results shown in the histogram are derived from three independent 
experiments in which at least 200 nuclei were scored for every experimental condition. The error bars represent SEM. Statistical analyses using ANO VA 
and Tukey’s multiple comparison of means test show significant differences in the percentage of nuclei undergoing PCC when comparing Rad18+/+ versus 
Rad18−/− MEFs (P < 0.01) and also when comparing Polk+/+ and Polk−/− cells (P < 0.01). There was no significant difference between Rad18−/− and Polk−/− 
cells basally or after MK-1775 treatment (P > 0.05), indicating that Polk−/− cells recapitulate the PCC phenotype of Rad18-null MEFs. (D–G) The indicated 
pairs of isogenic cell lines with mutations in Rad18, Polk, and POLH were treated with different doses of MK-1775, and sensitivity to Wee1/WEE1 inhibition 
was evaluated by clonogenic survival assays. For each experiment, the number of surviving colonies from MK-1775–treated cultures was expressed as a 
percentage of colony numbers from cells that received vehicle (DMSO) for control. On the survival curves, each data point represents the mean of triplicate 
determinations, and error bars represent the range. For each experiment, we performed a Student’s t test with the data obtained using 0.25 µM MK-1775. 
When comparing Rad18+/+ versus Rad18−/− cells or Polk+/+ versus Polk−/− cells, p was <0.01 (indicating that Rad18−/− and Polk−/− MEFs are MK-1775 
sensitive when compared with their respective WT control cell lines). When comparing XP30RO and XP30RO + Polη cells, p was <0.05, indicating that 
Polη-complemented XPV cells are MK-1775 sensitive when compared with Polη-deficient XPV patient cells. When comparing “knock-in” MEFs expressing 
RAD18 WT and RAD18 DC2, p was <0.01, indicating that MEFs expressing the RAD18 DC2 mutant cells are more MK-1775 tolerant than WT RAD18- 
expressing cells. All data shown are from representative experiments that were repeated at least three times and yielded similar results on each occasion. 
(H) Primary untransformed Rad18+/+ or Rad18−/− MEFs were cultured in 3% oxygen and infected with pMXs-derived retrovirus encoding HRASV12 or with 
empty retroviral vector for control. Retrovirus-infected cells were seeded in medium containing puromycin (1 µg/ml), and puromycin-resistant cells were 
enumerated every day for 1 wk. Data points represent means of triplicate determinations with error bars representing SEM. Using the data from the day 4 
post-infection time point, we performed ANO VA between groups followed by Tukey’s multiple comparison of means test to evaluate statistical significance 
of differences in growth of various genotypes. Results of the Tukey test were as follows: Rad18+/+ (empty vector) versus Rad18−/− (empty vector), P > 0.05 
(indicating no significant difference in proliferation of Rad18+/+ and Rad18−/− in the absence of oncogenic RAS); Rad18+/+ (empty vector) versus Rad18+/+ 
(RASV12), P < 0.01 (indicating significant stimulation of proliferation by oncogenic RAS in Rad18-replete cells); Rad18−/− (empty vector) versus Rad18−/− 
(RASV12), P < 0.01 (indicating significant inhibition of proliferation by RASV12 in Rad18-deficient cells). The cell proliferation data are from a representative 
experiment that yielded similar results on three separate occasions. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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Regardless of the proximal DNA replication structures 
that give rise to TLS pathway activation, ssDNA is clearly 
generated in response to aberrant CDK2 activity (Neelsen et 
al., 2013a) and most likely initiates TLS pathway activation. 
In many of our experiments, CDK2 led to increased chromatin 
loading of PCNA (in addition to PCNA monoubiquitination). 
Similarly, both PCNA and TLS polymerases are recruited to 
oxidative damage-induced ssDNA (Yang et al., 2013). It is es-
tablished that TLS can remediate post-replicative ssDNA gaps 
including ssDNA arising outside of S phase (Daigaku et al., 
2010; Zlatanou et al., 2011; Yang et al., 2013). Genomes con-
taining persistent ssDNA are vulnerable to nucleolytic attack 
and are likely to generate lethal DSBs. Collectively, our results 
indicate that RAD18-mediated repair synthesis prevents accu-
mulation of CDK2-induced ssDNA gaps in the genome.
Of the Y family DNA polymerases, Polη is the most ver-
satile enzyme and is probably the default TLS polymerase re-
cruited to most stalled DNA replication forks (Watanabe et al., 
2004). It is very clear that Polη resides constitutively in rep-
lication factories of unperturbed cells and facilitates tolerance 
of intrinsic replication stresses at fragile sites, telomeres, and 
probably elsewhere in the genome (Bétous et al., 2009; Ber-
goglio et al., 2013; Garcia-Exposito et al., 2016). It is unex-
pected therefore that Polκ but not Polη is specifically required 
for tolerance of CDK-induced replication stress. Moreover, it is 
surprising that Polη inhibits MK-1775 tolerance. When com-
pared with other TLS polymerases, Polη has a high affinity for 
PCNA conferred by a PLTH motif immediately flanking the 
C-terminal PCNA-interacting peptide box motif (Hishiki et al., 
2009; Durando et al., 2013; Despras et al., 2016). We speculate 
that the increased MK-1775 tolerance of Polη-compromised 
cells is caused by relief of competition with Polκ for access to 
replicating DNA. Regardless of whether Polη competes with 
Polκ for CDK2-induced replication intermediates, our results 
suggest a novel tumor-suppressive role for Polη in sensitizing 
cells to oncogenic DNA replication stress. Conversely, Polκ 
supports viability in the face of oncogenic stress and may 
facilitate tumorigenesis.
What, then, is the basis for Polκ dependency of MK-1775 
tolerance, and what are the putative DNA substrates that are 
preferentially replicated by Polκ? Persistent ssDNA is known to 
generate G4 structures (Cea et al., 2015), and TLS polymerases 
are implicated in the bypass of quadruplex DNA (Bétous et 
al., 2009). Polκ preferentially binds G4 when compared with 
non-G4 DNA, and Polκ activity is enhanced when the enzyme 
is within two to three nucleotides of a G4 motif (Eddy et al., 
2016). However, Polk−/− MEFs did not show increased sensitiv-
ity to the G4 stabilizer pyridostatin (PDS) when compared with 
Polk+/+ cells (Fig. S5). Therefore, reduced tolerance of quadru-
plex DNA cannot explain the MK-1775 sensitivity of Polk−/− 
cells. Interestingly, Rad18−/− cells were highly PDS sensitive, 
indicating that a Rad18 effector other than Polκ is necessary for 
G4 tolerance. Collectively, our results along with several recent 
studies (Despras et al., 2016; Garcia-Exposito et al., 2016) show 
that the different TLS pols have separable roles in processing 
distinct forms of intrinsically arising DNA replication stress.
Whether TLS polymerases evolved solely to cope with 
bulky chemically induced DNA lesions has been a subject of 
extensive debate. In this regard, we note that the TLS-defective 
(Rad18 and Polk mutant) cell lines used in this study are only 
modestly sensitive to UV light, and other bulky lesion-inducing 
agents yet show remarkable hypersensitivity to MK-1775. Our 
Figure 7. RAD18 confers MK-1775 tolerance in multiple cancer cells and cooperates with DSB repair genes to promote cell viability. (A–C) The indicated 
cancer cell lines were transfected with siRAD18 or control nontargeting siRNAs. 48 h later, cells were treated with the indicated doses of MK-1775, and 
drug sensitivities were determined using clonogenic survival assays. For each experiment, the number of surviving colonies from MK-1775–treated cultures 
was expressed as a percentage of colony number from cells that received vehicle (DMSO) for control. On the survival curves, each data point represents 
the mean of triplicate determinations, and error bars represent the range. For each experiment, we performed a Student’s t test with data obtained using 
the 0.3-µM MK-1775 concentration. When comparing siCon and siRAD18, p was <0.01 for all three cell lines, indicating that these cancer cells depend 
on RAD18 for MK-1775 tolerance. All data shown are from representative experiments that were repeated at least three times and yielded similar results 
on each occasion. (D) Cultures of isogenic Polk+/+ and Polk−/− MEFs were infected with lentiviruses encoding nontargeting control guide RNA or sgRNA 
targeting the murine Brca1 gene. After lentiviral transduction, pools of puromycin-resistant cells were treated with different concentrations of MK-1775, and 
sensitivity to Wee1 inhibition was evaluated by clonogenic survival assays. For each experiment, the number of surviving colonies from MK-1775–treated 
cultures was expressed as a percentage of colony number from cells that received vehicle (DMSO) for control. On the survival curves, each data point 
represents the mean of triplicate determinations, and error bars represent the range. For each dose of MK-1775, we performed ANO VA between groups 
followed by Tukey’s multiple comparison of means test. From results obtained with 0.2 µM MK-1775, either Polk or Brca1 deficiency led to MK-1775 
sensitivity (P = 0.006 for both genotypes when compared with Polk- and Brca1-replete controls), but there was no significant difference in the MK-1775 sen-
sitivity of Polk- and Brca1-deficient cells (P = 0.06). Combined loss of Polk and Brca1 led to increased MK-1775 sensitivity when compared with individual 
deficiencies in Polk−/− or sgBrca1 cells (P = 0.001), indicating that Brca1 and Polk are nonepistatic and have redundant roles in MK-1775 tolerance. The 
graph shown is from a single experiment that was repeated three times with similar results on each occasion. **, P < 0.01.
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results are consistent with the view that TLS serves primarily to 
respond to replicative stresses such as those induced by CDK2.
CDK2-induced oncogenic stress is often interchange-
ably modeled in cultured cells using overexpressed Cyclin E or 
MK-1775 treatment (Sogo et al., 2002; Beck et al., 2010, 2012; 
Neelsen et al., 2013a). However, these experimental approaches 
differ considerably in that MK-1775 de-represses both CDK2 
and CDK1 (which promote S phase and G2/M progression, re-
spectively), whereas Cyclin E activates only CDK2. Our stud-
ies with WEE1 inhibition and CDC25C overexpression reveal 
a requirement for an intact G2/M restriction point to repress 
phenotypic defects (such as persistent ssDNA in mitosis and 
PCC) that arise if TLS fails. Historically, the UV sensitivities of 
some XPV cell lines were only evident after caffeine treatment 
(Maher et al., 1976). Based on our results, the requirement for 
caffeine to reveal DNA damage sensitivity is most likely caused 
by inhibition of the ATR–CHK1 pathway and override of the 
G2/M replication checkpoint. Our results reveal extensive inter-
actions between TLS and multiple cell cycle and genome main-
tenance pathways: We demonstrate that p53 enforces G1 arrest 
and suppresses TLS activation in cells experiencing CDK2- 
induced replication stress. The G2/M replication checkpoint 
represses mitotic entry of TLS-defective cells containing un-
derreplicated DNA (Fig. 8). Finally, our analysis of interactions 
between Rad18/Polk and DSB repair genes (Polq and Brca1) in-
dicates that there is partial redundancy between TLS and HR for 
tolerance of CDK2 activity. Thus, TLS is a single component of 
a genome maintenance network comprising multiple pathways 
that collectively determine oncogenic stress tolerance.
Current paradigms suggest that diverse oncogenic stresses 
must be tolerated for neoplastic cells to bypass tumor-suppres-
sive barriers (Halazonetis et al., 2008). Our results suggest that 
RAD18/Polκ-mediated TLS could endow neoplastic cells with 
two important tumorigenic phenotypes: DNA damage/replica-
tion stress tolerance and error-prone (mutagenic) DNA synthe-
sis. Therefore, tumorigenesis may impose selective pressure 
for TLS proficiency. It is reported that Polκ is up-regulated in 
tumors (Bavoux et al., 2005), and our previous identification of 
a cancer cell–specific RAD18 activation mechanism (Gao et al., 
2016a,b) is also consistent with a role for TLS as a carcinogenic 
driver. Other DNA repair pathways are also elevated in some 
cancers. For example, POLQ (which we show in this study 
can confer tolerance of excess CDK2 activity) is up-regulated 
in BRCA1 mutant breast and ovarian cancers (Ceccaldi et al., 
2015). It will eventually be important to systematically define 
the roles of Rad18, Polk, and Polq in carcinogenesis in response 
to defined oncogenic drivers using mouse models.
An important byproduct of the selective pressure for DNA 
damage tolerance during tumorigenesis is the emergence of che-
moresistant cancer cells. If cancer cells are commonly depen-
dent on pathological DNA repair (via up-regulated TLS, TMEJ, 
or other mechanisms), those genome maintenance mechanisms 
represent molecular vulnerabilities that could be harnessed to 
sensitize cells to intrinsic or therapy-induced DNA damage. 
WEE1 inhibition is currently being considered as a therapeu-
tic strategy in cancer (Sakurikar et al., 2016). Our data show 
that the anticancer activity of MK-1775 and other WEE1 inhib-
itors could be improved with concurrent inhibition of the TLS 
pathway. In particular, our results suggest that BRCA1-deficient 
cells will be highly MK-1775 sensitive when TLS is inhibited.
Materials and methods
Cell culture and transfection
hTERT-expressing NHFs were provided by W. Kaufmann (University 
of North Carolina at Chapel Hill, Chapel Hill, NC). hTERT-expressing 
NHFs are diploid untransformed cells with no known mutations in on-
cogenes or tumor suppressors. Primary MEFs were derived from E13.5 
embryos of WT, Rad18−/−, Polk−/−, HA-RAD18-WT knock-in, and HA-
RAD18 (DC2) knock-in C57/BL6 mice as previously described (Bi et 
al., 2005; Yang et al., 2016). Polq−/− and isogenic Polq+/+ MEFs were 
provided by R. Wood (The University of Texas, Smithville, TX). With 
the exception of the engineered mutations in DNA repair genes, the 
MEFs used in this study are not known to harbor additional genetic 
lesions. Cancer cell lines H1299, A549, U2OS, and 293T were pur-
chased from ATCC and used for the described experiments without fur-
ther authentication. H1299 is a nonsmall cell lung carcinoma–adherent 
epithelial cell line that lacks p53 protein. A549 is a nonsmall cell lung 
carcinoma–adherent epithelial cell line which expresses WT p53 pro-
tein. U2OS is an osteosarcoma cell line with adherent epithelial mor-
phology that is intact for p53 and RB signaling. The 293T cell line was 
derived from the embryonic kidney and was transformed by sequential 
stable expression of the adenovirus E1A and E1B genes and SV40 large 
T antigen. NHFs harboring a doxycycline-inducible human Cyclin E 
cDNA were generated using the pIND UCER20 lentiviral vector (Meer-
Figure 8. Roles of Rad18 and Polκ in toler-
ance of CDK2-induced DNA replication stress. 
MK-1775 treatment de-represses CDK2 and 
CDK1 activities, which induce DNA replica-
tion stress and aberrant G2/M progression, 
respectively. Rad18 and Polκ prevent accumu-
lation of post-replicative ssDNA gaps arising 
from aberrant CDK2 activity. In the absence 
of Rad18 or Polκ, CDK2-induced ssDNA per-
sists into mitosis (because of aberrant CDK1 
activity) and triggers PCC.
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brey et al., 2011). XP30RO XPV and XP30RO + Polη fibroblast cells 
were provided by G. Stewart (University of Birmingham, Birmingham, 
England, UK). XP30RO cells are UV sensitive, owing to homozygous 
deletion of the 5′ region of the POLH gene, leading to expression of 
truncated and inactive Polη protein (Volpe and Cleaver, 1995). With 
the exception of mutations in the POLH gene, XP30RO cells are not 
known to harbor any genetic lesions. The XP30RO+ Polη cell line is a 
corrected derivative of XP03O cells that stably expresses WT Polh and 
displays normal UV sensitivity (Kannouche et al., 2001). All mouse and 
human fibroblasts and cancer cell lines were cultured in DMEM sup-
plemented with 10% FBS and 1% penicillin–streptomycin. XP30RO 
and XP30RO+ Polη cells were cultured in RPMI 1640 medium supple-
mented with 10% FBS and 1% penicillin–streptomycin. All cell lines 
tested negative for mycoplasma contamination as determined using the 
Universal Mycoplasma Detection kit (301012K; ATCC). Plasmid DNA 
and siRNA oligonucleotides were transfected using Lipofectamine 
2000 (Invitrogen) according to the manufacturer’s instructions except 
that plasmid DNA and Lipofectamine 2000 concentrations used in each 
transfection reaction were decreased by 50% to reduce toxicity.
Adenovirus construction and infection
The Tet-regulated Cyclin B adenovirus was constructed as previously 
described by Jin et al. (1998). All other adenoviruses were constructed 
and purified as described previously (Vaziri et al., 2003). In brief, 
cDNAs encoding various cell cycle regulators (including cyclins, 
oncogenes, and DNA replication and repair factors) were subcloned 
into the pACC MV shuttle vector. The resulting shuttle vectors were 
cotransfected with the pJM17 adenovirus plasmid into 293T cells. Re-
combinant adenovirus clones were isolated by plaque purification and 
verified by restriction analysis and Southern blotting. The empty vector 
AdCon (used to control for adenovirus infections) was derived simi-
larly but by cotransfection of the parental pACC MV shuttle vector with 
pJM17. Adenovirus particles were purified from 293T cell lysates by 
polyethylene glycol precipitation, CsCl gradient centrifugation, and gel 
filtration column chromatography. Adenovirus preparations were quan-
tified by A260 measurements. Cells were typically infected with 0.1−1.0 
× 1010 pfu/ml (as indicated in Figs. 1, 2, 3, and 4) by direct addition of 
purified virus to the culture medium.
RNA interference
For cancer cell lines, siRNAs were reverse transfected using Lipo-
fectamine 2000. In brief, siRNAs were incubated with Lipofectamine 
2000 and serum-free OptiMEM for 15 min at room temperature in the 
dark. Cells were then trypsinized and resuspended in 1  ml of Opti-
MEM and added directly into the siRNA/OptiMEM/Lipofectamine 
solution to give a plating density of 50%, and then they were incubated 
for 48 h. For NHFs and mouse fibroblasts, siRNAs were transfected 
using electroporation with a GenePulser Xcell (Bio-Rad Laborato-
ries). Electroporation was performed according to the manufacturer’s 
instructions. 200  µl PBS containing 107 cells and 5  µM siRNA was 
electroporated in a 0.2-cm cuvette using a 150 V, 10 ms, and 1 pulse 
for NHFs and using the preset 3T3 program (160 V and 500 µF) for 
mouse fibroblasts. Sequences of custom siRNA oligonucleotides used 
in this study are as follows: control nontargeting siRNA, 5′-UAG CGA 
CUA AAC ACA UCAA-3′; RAD18, 5′-GAG CAU GGA UUA UCU AUU 
CAA UU-3′; RNF8, 5′-GAG AAG CUU ACA GAU GUUU-3′; RPA32, 
5′-GGC TCC AAC CAA CAT TGTT-3′; NBS1, 5′-GUA CGU UGU UGG 
AAG GAAA-3′; Chk1, 5′-GCG UGC CGU AGA CUG UCCA-3′; Polκ, 
5′-GUA AAG AGG UUA AGG AAA-3′; Polη, 5′-GCA GAA AGG CAG 
AAA GUUA-3′; Cdc7, 5′-GCU CAG CAG GAA AGG AGUUdTdT-3′; 
and Cdc6, 5′-ACA AUU AAG UCU CCU AGCA-3′. siCDK1 was the 
ON-TAR GETplus SMA RTpool siRNA from GE Healthcare.
IP and immunoblotting
To prepare extracts containing soluble and chromatin-associated pro-
teins, monolayers of cultured cells typically in 10-cm plates were 
washed twice in ice-cold PBS and lysed in 500  µl of ice-cold cyto-
skeleton buffer (CSK buffer; 10  mM Pipes, pH 6.8, 100  mM NaCl, 
300 mM sucrose, 3 mM MgCl2, 1 mM EGTA, 1 mM dithiothreitol, 
0.1 mM ATP, 1 mM Na3VO4, 10 mM NaF, and 0.1% Triton X-100) 
freshly supplemented with protease inhibitor cocktail and PhosSTOP 
(Roche). Lysates were centrifuged at 4,000 rpm for 4 min to remove 
the CSK-insoluble nuclei. The detergent-insoluble nuclear fractions 
were washed once with 1 ml of CSK buffer and then resuspended in 
a minimal volume of CSK before analysis by SDS-PAGE and immu-
noblotting. For all IP experiments, input samples were sonicated and 
normalized for protein concentration. Magnetic beads containing cova-
lently conjugated antibodies against the HA tag (Cell Signaling Tech-
nology) were added to the extracts, and incubations were performed for 
30 min at 4°C using rotating racks. Immune complexes were recovered 
using magnetic stands. The beads were washed five times with 1 ml 
CSK (1 min per wash) to remove nonspecifically associated proteins. 
The washed immune complexes were boiled in protein loading buffer 
for 10 min to release and denature for SDS-PAGE.
For immunoblotting, cell extracts or immunoprecipitates were 
separated by SDS-PAGE, transferred to nitrocellulose membranes, 
and incubated overnight with the following primary antibodies: PCNA 
(sc-56), Chk1 (sc-7898), β-actin (sc-130656), cyclin E (sc-198), GAP 
DH (sc-32233), Rnf8 (SC-134492), Cdc6 (SC-9964), and GFP (SC-
9996) from Santa Cruz Biotechnology, Inc.; Cdt1 (A300-786A), 
pRPA32 S4/8 (A300-245A), Polη (A301-231A), Polι (A301-304A), 
Polκ (A301-977A), and RAD18 (A301-340A) from Bethyl Labo-
ratories, Inc.; p42 MAPK (9107), p-Cdc2 Y15 (9111), p-Chk1 S317 
(2344), and p-Chk2 (2661) antibodies were purchased from Cell Sig-
naling Technology; γH2AX (05-636) and RPA34/RPA32 (NA19L) 
were from EMD Millipore; CDC7 (DCS-342) was from MED ICAL 
& BIO LOG ICAL LAB ORA TOR IES CO.; and Cdc45 rat monoclo-
nal antibody was as previously described (Liu et al., 2006). Antibody 
dilutions used for immunoblotting were 1:1,000 with exceptions for 
the following antibodies: PCNA (1:500), β-actin (1:5,000), GAP DH 
(1:5,000), and γH2AX (1:10,000).
CDK2 activity assays
CDK2 activities were determined by IP–kinase assays as described by 
Rosenblatt et al. (1992). In brief, cells were lysed in CSK as described 
in the IP and immunoblotting section. Lysates were clarified by centrif-
ugation (10,000 g for 10 min), normalized for protein content (typically 
∼500 µg protein in 0.5 ml), and immunoprecipitated with anti-CDK2 
antibody (sc-163) or control IgG using magnetic beads as described 
in Fig. 1 C. After the final CSK wash, beads were washed in 50 mM 
Hepes, pH 7.4, and 1 mM dithiothreitol and then combined with a 30-µl 
reaction mix containing 10 µg of histone H1 (Sigma-Aldrich), 50 µM 
ATP, 10 mM MgCl2, and 2.5 µCi of [γ-32P]ATP (3,000 Ci/mmol; NEN). 
After a 15-min incubation at room temperature, reaction mixtures were 
boiled in Laemmli sample buffer and then resolved by SDS-PAGE 
using 12% gels. After electrophoresis, gels were fixed in 40% meth-
anol/10% acetic acid containing 0.05% Coomassie blue dye and then 
were washed extensively in 40% methanol/10% acetic acid to remove 
unincorporated radioisotope. Phosphorylated histone bands were visu-
alized by autoradiography of the dried gels.
COM ET assay
Relative levels of DNA strand breaks were measured by a single-cell 
gel electrophoresis assay (Olive et al., 1990) using a commercially 
available COM ET Assay kit (Trevigen). For COM ET assays, NHF 
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cells were plated in six-well dishes at a density of 0.5 × 105 cells per 
well. Oncogenes (Ha-RAS, MYC, Cyclin E, and CDT1) were delivered 
to cells by infection with 1010 pfu/ml of purified adenoviral vectors. 
After 24 h, cells were embedded in agarose and subjected to electro-
phoresis according to the manufacturer’s instructions. Cells were visu-
alized using an IX61 inverted microscope (Olympus), and images of 
cells were acquired as TIFF files. For each experimental condition, “tail 
moments” (defined as the product of tail length and the fraction of total 
DNA in the tail) were determined for 50 nuclei using ImageJ software 
(National Institutes of Health) with the COM ET assay plugins (original 
macro from Herbert M. Geller, added by Robert Bagnell). To compare 
tail moments between experimental groups, we performed ANO VAs 
followed by Tukey’s tests to correct for experiment-wide error rates 
between multiple comparisons.
Analysis of DNA replication dynamics using DNA fiber assays
Growing cells were pulse labeled for 20 min with 25 µM of the thymi-
dine analogue chlorodeoxyuridine (CIdU; C6891; Sigma-Aldrich). At 
the end of the CldU-labeling period, cells were washed twice with a 
warm medium and immediately pulse labeled for 20 min with 250 µM 
of idodeoxyuridine (IdU; I7125; Sigma-Aldrich). Labeled cells were 
harvested and DNA fiber spreads were prepared and stained exactly 
as described previously by Jones et al. (2013). Images of stained DNA 
fibers were acquired on a 710 confocal microscope (UNC Microscopy 
Services Laboratory; ZEI SS) using a 20× lens. The lengths of CldU 
(AF 555; red)- and IdU (AF 488; green)-labeled fibers were measured 
using the ImageJ software, and micrometer values were converted into 
kilobases using the conversion factor 1 µM = 2.94 kb (one bp corre-
sponds to ∼340 pm). 50 representative DNA fibers were measured for 
each experimental condition. Prism 6 (GraphPad Software) was used 
for variation analysis and to generate dot plots. Fiber distribution fig-
ures were generated using the RColorBrewer package in R.
Clonogenic survival assays
For experiments in MEFs, cells were seeded at a density of 1,000 cells/
well in triplicate in six-well dishes. The WEE1 inhibitor MK-1775 
was diluted in growth medium and added directly to the cells for 24 h 
before switching to fresh medium. Growth medium was replenished 
every 3 d. Colonies containing ∼50 surviving cells were stained with 
0.05% crystal violet in 1× PBS containing 1% methanol and 1% form-
aldehyde. The ImageJ plugin ColonyArea (Guzmán et al., 2014) was 
used to automatically quantify stained colonies. In some experiments, 
lentivirally expressed sgRNAs were used to functionally inactivate 
PolQ and Brca1 genes exactly as described previously (Wyatt et al., 
2016). In brief, MEFs were infected with lentivirus encoding Cas9 and 
either control nontargeting guides or sgRNAs targeting mouse PolQ 
and Brca1 genes. Lentivirus-infected cells were selected in puromy-
cin-containing medium for 3 d. Puromycin-resistant cells were seeded 
at a density of 1,000 cells/well in triplicate six-well dishes, treated with 
MK-1775, and analyzed for clonogenic survival exactly as described 
in Figs. 7 D and S4. The PolQ sgRNA was validated as previously de-
scribed (Wyatt et al., 2016). To validate the gene editing experiments, 
quantitative PCR was used to measure Brca1 mRNA levels in puro-
mycin-selected cells. The quantitative PCR primer sequences used in 
these experiments were 5′-CTG CCG TCC AAA TTC AAG AAGT-3′ 
and 5′-CTT GTG CTT CCC TGT AGG CT-3′ (corresponding with Brca1 
forward and reverse primers, respectively). As a positive control for 
the quantitative PCR reactions, β-actin mRNA was amplified using 
the primers 5′-TTC TTT GCA GCT CCT TCG TTG CCG-3′ (forward) 
and 5′-TGG ATG GCT ACG TAC ATG GCT GGG-3′ (reverse). In three 
independent experiments, Brca1 mRNA was reduced by 54 ± 4% in 
sgBrca1-transduced MEFs when compared with controls. After lenti-
viral transduction, pools of puromycin-resistant cells were seeded in 
six-well plates and treated with different concentrations of MK-1775. 
Cell sensitivity to Wee1 inhibition was evaluated by clonogenic sur-
vival assay. For experiments in the cancer cell lines, siRNA transfec-
tions were performed as described in the RNA interference section. 
24 h after transfection, cells were seeded at a density of 1,000 cells/well 
in triplicate six-well dishes. MK-1775 treatments and colony-forming 
assays were performed exactly as described above.
Flow cytometry
To detect ssDNA, growing cells were first cultured for 24 h in medium 
containing 10 µM BrdU to label genomic DNA. Cell monolayers were 
washed to remove unincorporated BrdU, placed in fresh BrdU-free me-
dium, and returned to the incubator. After treatment with genotoxins 
or oncogenes as described in all figure legends, cells were harvested 
by trypsinization, washed in PBS, resuspended in 65% PBS with 35% 
ethanol, and fixed by overnight incubation at 4°C.  Fixed cells were 
stained with fluorescent anti-BrdU antibodies (FITC mouse anti-BrdU 
kit; 556028; BD) without prior acid treatment to detect only ssDNA. 
To confirm that the experimental cells had incorporated BrdU, aliquots 
of all nuclei were also denatured using HCl and then neutralized with 
borax before staining with anti-BrdU antibody. For cell cycle analysis, 
nuclei were incubated in 1× PBS containing 10 µg/ml of propidium io-
dide and 1 µg/ml of RNaseA to stain total DNA. Stained cells were an-
alyzed by flow cytometry on an Accuri C6 flow cytometer (BD) using 
the manufacturer’s software.
Fluorescence microscopy
To visualize nuclear foci containing TLS proteins, U2OS cells were 
grown to ∼50% confluency on glass-bottomed plates (MatTek Corpora-
tion) then infected with AdYFP-Polη (5 × 108 pfu/ml), AdGFP-Polκ (109 
pfu/ml), AdCFP-RAD18 (4 × 109) pfu/ml, or equivalent concentrations 
of an “empty” control adenovirus (AdCon). To induce replication stress 
by Cyclin E overexpression, cells were coinfected with 109 pfu/ml of Ad-
Cyclin E adenovirus and fixed 24 h after infection. To induce replication 
stress with WEE1 inhibition, cells were treated with 0.25 µM MK-1775 
18 h after viral infection and then fixed 24 h after infection. At the time 
of harvesting, cells were washed three times with PBS and then extracted 
for 5 min in cold CSK buffer and fixed for 10 min in 2% PFA in PBS. 
For PCNA staining, cells were fixed with cold methanol for 20 min at 
−20°C instead of PFA. For experiments not requiring antibody staining, 
cells were covered with VEC TAS HIE LD Antifade Mounting Medium 
containing DAPI (Vector Laboratories) and imaged within 2 h. For an-
tibody staining, cells were blocked in 3% BSA + 5% normal donkey 
serum in PBS for 1 h and then incubated in primary antibody for 1 h at 
room temperature. Cells were washed three times with PBS and then 
incubated with secondary antibody (1:300) for 1 h at room temperature. 
After three washes with PBS, cells were covered with Vectashield Solu-
tion and imaged within 2 h. Antibodies used for fluorescence microscopy 
in this study were: mouse-RPA32 (1:200; ab2), mouse-G4 (1:200; 1H6), 
and rabbit anti–phosphor-H3 (1:400; 06-570) from EMD Millipore, and 
rabbit-53BP1 (1:300; sc-22760) and mouse PCNA (1:500; sc-56) from 
Santa Cruz Biotechnology, Inc. Fixed-cell imaging was performed in the 
University of North Carolina Microscopy Services Laboratory core fa-
cility using an LSM700 confocal laser scanning microscope (ZEI SS) and 
the following objective lenses: Plan Apochromat 20×/0.80 differential 
interference contrast II/0.8 NA, Plan-NEO FLU AR 40×/1.30 oil/1.3 NA, 
and Plan Apochromat 63×/1.4 oil differential interference contrast/1.4 
NA. Imaging was performed at 25°C. Flourochromes used were DAPI, 
Alexa Fluor 488, and Alexa Fluor 647. Images were acquired directly 
using ZEN 2011 Acquisition software (ZEI SS). Images were analyzed 
using ImageJ and saved as TIFF files with no further adjustment.
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Mitotic spreads
Mitotic spreads were prepared and analyzed for PCC assays as de-
scribed previously (Nghiem et al., 2001). After a 6-h incubation with 
0.25 µM MK-1775 (or DMSO for controls), cells were harvested with 
trypsin and collected by centrifugation at 300 g for 10 min. Cell pellets 
were resuspended by gentle pipetting in 10  ml of 75  mM KCl, and 
the resulting suspensions were incubated for 10 min at room tempera-
ture. Cells were then collected by centrifugation (300 g for 10 min) 
and resuspended in 5 ml of freshly prepared Carnoy’s fixative (three 
parts methanol and one part glacial acetic acid) and incubated for 10 
min at room temperature. Fixed cells were collected by centrifugation 
(300 g and 10 min) and resuspended in 200 µl of Carnoy’s fixative. 
10 µl of each cell suspension was dropped from a height of 10 cm onto 
a glass slide and allowed to dry. 15 µl of DAPI solution (Vectashield 
antifade mounting medium with DAPI fluorochrome) was spotted onto 
each slide. Coverslips were gently placed above the DAPI droplet, and 
edges were sealed with clear nail polish. A BX61 upright widefield 
fluorescence microscope (Olympus) was used to identify and count 
mitotic cells that had characteristic features of either a normal mitosis 
or PCC. Imaging was performed at 25°C using a Plan Apochromat N 
60×/1.42 oil UIS 2 BFP1 objective lens with an NA of 1.42. Images 
were acquired using an ORCA RC camera (Hamamatsu Photonics) 
and Improvision’s Velocity software. Subsequent to acquisition, images 
were analyzed with ImageJ and saved as TIFF files with no additional 
adjustment. 200 metaphase cells were scored for each independent ex-
periment, and percentages of PCC were calculated using compiled data 
from three separate experiments.
Statistics
Statistical analyses were performed using Prism 6. The unpaired two-
tailed Student’s t test was used to compare two datasets in various ex-
periments as indicated in the figure legends. In some experiments in 
which more than two datasets were compared, we performed ANO VA 
with post hoc Tukey’s honest significance difference test. On graphs 
and charts, asterisks indicate p-values: *, P < 0.05; **, P < 0.01; ***, P 
< 0.001. P > 0.05 indicates a difference that is not significant.
Online supplemental material
Fig. S1 is related to Fig. 1 and tests the differential effects of various 
CDK2 and CDK1 activators (including Cyclins E, A, B, and CDC25C) 
on PCNA monoubiquitination. Fig. S2 shows validation of the flow cy-
tometry–based ssDNA assays used in Figs. 3 and 5. Fig. S3 shows that 
bypass of the G2/M checkpoint by overexpressed CDC25C promotes 
the accumulation of mitotic cells harboring persistent ssDNA. Fig. S4 
shows that Polq-deficient cells lacking Polθ (the key mediator of the 
alternative end-joining DSB repair pathway) are sensitive to MK-1775. 
Fig. S5 shows that Rad18 and Polkκ have separable roles in tolerance 
of the G4 quadruplex DNA-stabilizing agent PDS.
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